Clomacran Phosphate

CHEMBL2104136 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

398.8 g/mol

LogP

—

Phase

4

A phosphate salt form of clomacran that delivers the same antipsychotic effects as the parent compound. It is used to help control symptoms of psychosis and related mental health disorders.

Berat Molekul

398,8000 g/mol

TPSA

93,00 Å²

Mekanisme Kerja

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)CCCC1c2ccccc2Nc2ccc(Cl)cc21.O=P(O)(O)O

InChI

InChI=1S/C18H21ClN2.H3O4P/c1-21(2)11-5-7-14-15-6-3-4-8-17(15)20-18-10-9-13(19)12-16(14)18;1-5(2,3)4/h3-4,6,8-10,12,14,20H,5,7,11H2,1-2H3;(H3,1,2,3,4)

Molecular Formula

C18H24ClN2O4P

HBD / HBA

4 / 6

Ikatan yang Dapat Dirotasi

4

Atom Berat

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A phosphate salt form of clomacran that delivers the same antipsychotic effects as the parent compound. It is used to help control symptoms of psychosis and related mental health disorders.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Clomacran Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2104136. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23724848. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Clomacran Phosphate di PillFYI

Struktur

Data Cepat

Rumus: C18H24ClN2O4P

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.